LA JOLLA PHARMACEUTICAL COMPANY (NASDAQ:LJPC) Files An 8-K Other EventsItem 8.01OTHER EVENTS.
On September 25, 2017, La Jolla Pharmaceutical Company (the "Company") issued a press release announcing that the European Medicines Agency’s Committee for Medicinal Products for Human Use issued favorable Scientific Advice regarding the EU regulatory pathway for LJPC-501 (angiotensin II). Based on this Advice, the Company intends to submit a Marketing Authorization Application for LJPC-501 in the third quarter of 2018. A copy of the press release is attached as Exhibit 99.1 to this Current Report onForm8-K.
Item 8.01 FINANCIAL STATMENTS AND EXHIBITS.
(d)Exhibits. The following exhibits are filed with this report on Form 8-K:
|
Exhibit No. |
Description |
|
Press Release dated September 25, 2017
|
LA JOLLA PHARMACEUTICAL CO ExhibitEX-99.1 2 emascientificadvice.htm EXHIBIT 99.1 Exhibit La Jolla Pharmaceutical Company Announces Intent to Submit Marketing Authorization Application for LJPC-501 in the Third Quarter of 2018– Decision follows successful Scientific Advice meeting with European Medicines Agency –SAN DIEGO,…To view the full exhibit click here
About LA JOLLA PHARMACEUTICAL COMPANY (NASDAQ:LJPC)
La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. It is engaged in the research, development and commercialization of its technologies and drug candidates for pharmaceutical products. Its product candidates in development include LJPC-501, LJPC-401, LJPC-30Sa and LJPC-30Sb. The Company is developing LJPC-501 for the treatment of catecholamine-resistant hypotension (CRH). The Company is developing LJPC-401 for the treatment of iron overload, which occurs as a result of diseases, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. It is developing LJPC-30Sa and LJPC-30Sb not only for the treatment of serious bacterial infections but also for the potential treatment of rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.